Transforming Trial Design and Patient Data with Deterministic AI - with Emma Vitalini of Amgen (27 min)
ai-driven-innovation-economy ai-for-personalized-medicine ai-governance-laws ai-literacy-public-awareness privacy-in-the-ai-era
- Release date: 2026-01-20
- Listen on Spotify: Open episode
- Episode description:
Today's guest is Emma Vitalini, Head of Global Digital Health Technology Innovation at Amgen, where she leads initiatives at the intersection of digital health, data strategy, and clinical innovation. Emma joins Emerj Editorial Senior Editor Marilie Fouche to explore how data and AI are reshaping patient recruitment, consent, and execution in clinical trials, with a focus on decentralized models, scalable compliance, and explainable AI in regulated environments. Emma also shares practical guidance for enterprise leaders on where AI is delivering near-term ROI today, including accelerating patient screening by surfacing unstructured data, reducing enrollment delays through digital and remote monitoring tools, and designing modular, plug-and-play AI platforms that balance speed, flexibility, and regulatory trust. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Summary
- ๐ Real-Time Data Wins: AI enables early detection of data gaps and quality issues, shifting from periodic collation to proactive monitoring for faster trial closure.
- ๐ฏ Smart Site Selection: Leveraging AI on site performance data predicts recruitment speed and resource needs, avoiding bottlenecks in global trials.
- ๐ฅ Digital Twins Revolution: Intelligent patient twins simulate experiences, model doses, and create synthetic cohorts to cut timelines, dropouts, and ethical concerns like placebos.
- ๐ Federated Data Future: Privacy-preserving federated access to diverse global data unlocks personalized medicine without compromising GDPR or trust.
- ๐ค Bottom-Up Adoption: Involving teams early with compliance, modular tools, and mindset shifts ensures scalable AI ROI in regulated environments.
Insights
How can AI transform site selection and performance monitoring to accelerate clinical trial recruitment?
Time: 6:09 โ 7:19
Category: AI for Personalized Medicine, AI-Driven Innovation EconomyAnswer: AI analyzes historical site data to identify top performers and areas with high disease concentrations, reducing bottlenecks from resource shortages or competing trials. This enables faster patient enrollment and ensures medicines reach patients sooner. (Start at 6:09)
What role do intelligent digital health twins play in reducing patient dropouts and trial durations?
Time: 8:20 โ 14:12
Category: AI for Personalized Medicine, AI Governance & LawsAnswer: Digital twins simulate patient experiences pre-enrollment, allowing better understanding and preparation, while also enabling dose modeling, synthetic populations, and what-if scenarios to enrich cohorts and potentially eliminate placebo arms ethically. FDA and EMA guidances support this for faster efficacy signals. (Start at 8:20)
Why is federated data access essential for overcoming diversity gaps in clinical trials?
Time: 14:50 โ 18:21
Category: Privacy in the AI Era, AI Governance & LawsAnswer: Global data restrictions limit diverse training datasets; federated models allow querying without data movement, preserving privacy via APIs like EU CanCan, enabling richer genomic/proteomic insights while complying with GDPR. (Start at 14:50)
How does a bottom-up approach with mindset shifts drive AI adoption in clinical operations?
Time: 18:21 โ 21:49
Category: AI-Driven Innovation Economy, AI Literacy & Public AwarenessAnswer: Top-down mandates fail due to change fatigue; empowering individuals with tools like Copilot, intake processes for use cases, and orchestrating modular improvements fosters buy-in and faster evolution across end-to-end workflows. (Start at 18:21)
Why must compliance and legal teams be involved from day one in AI trial innovations?
Time: 21:49 โ 22:54
Category: AI Governance & Laws, Privacy in the AI EraAnswer: Early alignment ensures regulatory approval as software-as-medical-device, builds trust with patients/HCPs, and creates flexible, global-compliant platforms amid varying data laws, accelerating safe deployment. (Start at 21:49)
Where does AI deliver the highest ROI in clinical trials without overhauling infrastructure?
Time: 24:14 โ 25:08
Category: AI-Driven Innovation EconomyAnswer: Targeting constrained workflows like unstructured data surfacing, screening acceleration, and rework reduction shortens timelines; starting with low-risk use cases builds confidence for advanced patient-facing tech. (Start at 24:14)